enteroviru
one
major
agent
caus
hand
foot
mouth
diseas
hfmd
infant
young
children
character
fever
ulcer
oral
mucosa
vesicl
hand
although
infect
case
selflimit
also
induc
sever
neurolog
complic
asept
mening
enceph
brainstem
enceph
pulmonari
edema
pe
rarer
neurolog
complic
sometim
lead
perman
neurolog
sequela
even
death
fatal
pe
cardiorespiratori
failur
thought
main
diseas
process
fatal
also
postul
dysregul
inflammatori
respons
cellular
immun
possibl
respons
instanc
vitro
studi
conduct
lu
et
al
show
inhibit
cellular
type
ifn
respons
target
subunit
ifn
receptor
anim
studi
reveal
lymphocyt
antibodi
respons
reduc
mortal
tissu
viral
load
clinic
studi
shown
elev
cytokin
product
includ
lymphocyt
includ
cell
cell
natur
killer
cell
deplet
respons
unfortun
date
effect
vaccin
therapi
avail
infect
therefor
develop
better
understand
neuropathogenesi
infect
utmost
import
develop
effect
clinic
therapi
treat
hmfd
patient
chemokin
group
small
secret
protein
shown
induc
direct
chemotaxi
respons
investig
chemokin
belong
cc
cxc
famili
classifi
rel
posit
first
consensu
cystein
either
separ
nonconserv
amino
acid
next
cc
chemokin
includ
regul
upon
activ
normal
cell
express
secret
rant
also
term
monocyt
chemoattract
also
term
protein
also
term
monokin
induc
mig
also
term
also
term
belong
cxc
although
initi
character
import
inflamm
target
leukocyt
chemokin
consid
crucial
mediat
play
fundament
role
physiolog
patholog
immun
exampl
concentr
rant
higher
patient
bacteri
infect
includ
sepsi
communityacquir
pneumonia
skin
abscess
control
infect
indic
rant
may
involv
pathogenesi
studi
uniqu
pattern
immun
respons
high
level
low
level
found
patient
mig
significantli
elev
sputum
asthma
patient
compar
healthi
similarli
plasma
level
mig
significantli
higher
patient
pe
uncompl
indic
overexpress
chemokin
cascad
appear
play
import
role
immun
respons
howev
studi
evalu
level
chemokin
cerebrospin
fluid
csf
hmfd
children
addit
enceph
common
neurolog
complic
infect
littl
known
role
chemokin
enceph
key
mediat
underli
inflammatori
respons
remain
unclear
moreov
despit
sever
consequ
earli
recognit
hfmd
patient
neurolog
complic
import
select
optim
intens
care
might
prevent
diseas
progress
therefor
purpos
studi
evalu
csf
level
chemokin
rant
mig
hfmd
patient
enceph
ii
identifi
possibl
interrelationship
chemokin
csf
paramet
iii
investig
potenti
role
hfmd
biomark
reflect
pathogenesi
may
pave
way
new
therapeut
target
studi
includ
hfmd
patient
enceph
fc
patient
control
baselin
characterist
studi
popul
list
tabl
brief
signific
differ
enceph
fc
patient
regard
age
gender
cell
number
blood
howev
enceph
patient
like
longer
durat
fever
hospit
stay
higher
blood
glucos
higher
wbc
protein
concentr
csf
compar
children
fc
csf
chemokin
level
pgml
rant
pgml
mig
pgml
pgml
significantli
higher
patient
enceph
acut
stage
compar
fc
pgml
pgml
pgml
pgml
respect
fig
b
c
e
csf
level
contrari
significantli
lower
enceph
group
pgml
compar
fc
group
pgml
fig
furthermor
investig
associ
chemokin
level
acut
phase
fever
durat
admiss
posit
correl
rant
fever
durat
admiss
r
p
howev
r
p
r
p
neg
correl
fever
durat
admiss
addit
neither
mig
r
p
r
p
associ
fever
durat
admiss
compar
acut
stage
csf
chemokin
level
pgml
vs
pgml
rant
pgml
vs
pgml
mig
pgml
vs
pgml
pgml
vs
pgml
significantli
decreas
convalesc
stage
fig
b
c
e
enceph
patient
except
pgml
vs
pgml
fig
enceph
patient
csf
cytolog
variabl
includ
wbc
neutrophil
percentag
lymphocyt
percentag
strongli
associ
csf
level
fig
although
csf
mig
concentr
correl
well
csf
wbc
fig
show
poor
correl
neutrophil
lymphocyt
percentag
fig
n
contrast
statist
signific
correl
csf
rant
level
neutrophil
lymphocyt
percentag
fig
f
k
l
detect
correl
csf
wbc
found
fig
j
find
correl
csf
chemokin
level
cytolog
variabl
fc
patient
supplementari
tabl
given
mark
variat
csf
chemokin
hfmd
patient
enceph
perform
characterist
csf
chemokin
differenti
enceph
fc
evalu
roc
shown
tabl
fig
roc
analys
show
mig
yield
significantli
increas
area
roc
respect
compar
rant
youdenindexcalcul
provid
sensit
specif
cutoff
pgml
fig
cutoff
point
mig
pgml
sensit
specif
respect
fig
similarli
rant
sensit
specif
optim
cutoff
valu
pgml
pgml
pg
respect
fig
b
subsequ
combin
marker
five
chemokin
evalu
roc
analysi
area
roc
curv
tabl
sensit
specif
respect
fig
henc
diagnost
effici
combin
marker
superior
singl
chemokin
corrobor
observ
correl
interrel
analysi
perform
within
csf
chemokin
shown
fig
posit
correl
mig
wherea
neg
correl
rant
strongli
associ
fig
likewis
mig
associ
rant
fig
note
strong
correl
mig
fig
furthermor
find
correl
mig
fig
similarli
signific
correl
fig
increas
evid
suggest
cellular
humor
immun
dysfunct
involv
exacerb
still
effect
infect
host
adapt
immun
especi
chemokin
well
understood
present
studi
chemokin
rant
mig
found
significantli
chang
csf
hfmd
patient
acut
stage
enceph
fig
find
suggest
chemokin
function
select
recruit
leukocyt
popul
involv
patholog
central
nervou
system
cn
infect
increas
express
level
mig
consist
previou
addit
found
chemokin
correl
fig
accord
result
string
bioinformat
show
chemokin
act
cooper
rather
alon
supplementari
fig
likewis
cytokin
storm
consid
main
trigger
cardiopulmonari
taken
togeth
evid
impli
dysregul
chemokin
cascad
cn
appear
import
regard
elicit
inflammatori
respons
infect
chemokin
highli
involv
regul
leukocyt
migrat
may
provid
explan
signific
correl
chemokin
csf
cytolog
mig
cell
attract
chemokin
rant
recruit
previou
studi
shown
hfmd
line
find
also
show
chemotact
factor
includ
mig
rant
rather
potent
chemoattract
significantli
elev
acut
phase
thu
assum
increas
csf
mig
rant
children
enceph
may
result
enhanc
lymphocyt
recruit
cn
accordingli
decreas
express
chemokin
enceph
patient
may
contribut
diminish
antagon
effect
cytokin
product
henc
intensifi
predomin
interestingli
reveal
mig
rant
decreas
recoveri
phase
signific
differ
observ
togeth
data
impli
chemoattract
predomin
infect
contribut
host
defens
promot
protect
respons
mig
ifninduc
cxc
chemokin
potent
chemoattract
activ
cell
memori
cell
natur
killer
cell
signal
could
explain
mig
strongli
posit
correl
reflect
tempor
cooper
ligand
abund
data
demonstr
mig
induc
divers
spectrum
neuroimmun
diseas
influenc
shen
et
al
observ
overexpress
increas
mig
level
reduc
viral
burden
multipl
tissu
increas
surviv
mice
consist
mig
significantli
increas
present
studi
sinc
chemokin
produc
cn
cell
within
hour
suppos
increas
chemokin
level
patient
enceph
may
mediat
earli
regul
recruit
protect
immun
reduc
tissu
damag
likewis
report
mice
infect
neurotrop
mous
hepat
viru
reduc
mig
level
fail
control
viral
replic
kuang
et
al
show
enhanc
bloodbrain
barrier
bbb
attenu
rabi
viru
rabv
evid
suggest
earli
express
mig
within
cn
viru
infect
import
initi
maintain
protect
immun
respons
howev
implic
herp
simplex
viru
hsv
sever
acut
respiratori
syndrom
sar
lymphocyt
choriomening
viru
lcmv
aggrav
detail
exagger
activ
mig
propos
associ
advers
outcom
intens
care
unit
admiss
death
increas
secret
eye
facilit
spread
hsv
restrict
site
within
regul
sever
lcmvinduc
inflammatori
process
result
fatal
collect
studi
demonstr
subtl
perhap
diverg
role
differ
viru
infect
note
analyz
csf
level
mig
well
potenti
biomark
enceph
found
highest
potenti
distinguish
enceph
patient
fc
patient
high
sensit
specif
follow
mig
similarli
previou
studi
show
csf
plasma
ratio
mig
tend
increas
increas
sever
diseas
csf
level
patient
significantli
higher
plasma
level
control
moreov
establish
antivir
treatment
avail
hfmd
therefor
result
indic
mig
might
novel
biomark
diagnos
enceph
may
guid
patient
treatment
clinic
practic
although
signific
differ
mig
determin
csf
number
detect
case
larg
enough
power
solo
diagnost
biomark
enceph
moreov
perform
roc
analysi
analyz
diagnost
effici
marker
enceph
show
sensit
csf
mig
low
howev
combin
marker
five
chemokin
signific
elev
area
roc
sensit
detect
enceph
therefor
combin
five
chemokin
could
appli
clinic
diagnosi
enceph
may
potenti
serv
monitor
diseas
progress
guid
clinic
diagnosi
treatment
level
howev
present
differ
pattern
low
concentr
patient
enceph
compar
fc
patient
similarli
wang
et
al
show
ratio
mean
csf
plasma
level
tend
fall
increas
diseas
result
suggest
may
contribut
overwhelm
diseas
process
invers
shown
plasma
mcp
level
elev
increas
diseas
could
explain
differ
immun
respons
system
local
inflammatori
respons
interest
although
level
decreas
convalesc
statist
signific
differ
level
acut
recoveri
phase
may
associ
small
pair
sampl
size
better
elucid
aspect
would
interest
determin
level
larger
scale
one
timepoint
studi
limit
small
pair
sampl
size
singl
timepoint
case
moreov
control
group
includ
healthi
children
without
underli
diseas
ethic
issu
despit
limit
associ
studi
group
popul
present
find
enhanc
understand
pathogenesi
provid
strategi
better
biomarkertherapeut
target
infect
conclus
detect
csf
level
four
chemokin
rant
mig
significantli
elev
hmfd
patient
enceph
importantli
result
correl
roc
curv
analys
indic
csf
mig
may
clinic
diagnost
valu
enceph
addit
studi
need
valid
whether
mig
could
therapeut
target
infect
thu
find
provid
import
insight
role
chemokin
pathogenesi
infect
studi
carri
children
hospit
zhejiang
univers
school
medicin
hangzhou
children
hospit
april
august
approv
ethic
committe
hospit
method
conduct
accord
declar
helsinki
written
inform
consent
obtain
children
parent
guardian
prior
enrol
patient
identifi
refer
enrol
senior
physician
care
examin
evalu
diagnosi
hfmd
determin
base
popular
vesicular
rash
hand
feet
mouth
buttock
usual
accompani
fever
enceph
defin
presenc
alter
level
conscious
includ
lethargi
drowsi
coma
seizur
myoclonu
csf
pleocytosi
addit
patient
simpl
febril
convuls
fc
enrol
control
diagnosi
fc
base
criteria
describ
brief
simpl
fc
defin
gener
tonicclon
seizur
occur
first
hr
febril
ill
last
less
min
without
focal
sign
recur
within
hr
associ
evid
intracrani
infect
metabol
enrol
throat
swab
rectal
swab
collect
particip
meanwhil
lumbar
punctur
taken
obtain
acut
phase
csf
sampl
patient
clinic
sampl
hfmd
patient
mention
taken
time
within
day
hfmd
symptom
onset
unfortun
recoveri
phase
csf
sampl
obtain
hfmd
patient
enceph
sampl
store
analysi
clinic
data
particip
collect
review
electron
medic
record
hospit
includ
age
gender
hematologicalparamet
csf
cytolog
csf
biochem
marker
genom
detect
throat
rectal
specimen
realtim
rtpcr
describ
brief
total
rna
extract
specimen
use
viral
rna
mini
kit
qiagen
hilden
germani
revers
transcrib
cdna
primescript
rt
reagent
kit
da
gene
guangzhou
china
qpcr
reaction
base
taqman
technolog
perform
use
realtim
rtpcr
system
appli
biosystem
foster
ca
usa
cytometr
bead
array
cba
use
measur
panel
chemokin
name
rant
mig
short
use
standard
sampl
dilut
assay
perform
accord
manufactur
recommend
bd
cba
human
chemokin
kit
bd
bioscienc
san
diego
ca
usa
analyz
facscalibur
flow
cytomet
becton
dickinson
ca
usa
statist
analysi
perform
spss
softwar
version
spss
chicago
il
usa
variabl
repres
mean
sd
normal
distribut
data
median
interquartil
rang
nonparametr
distribut
data
accordingli
differ
group
estim
student
ttest
normal
distribut
data
mannwhitney
u
test
nonparametr
distribut
data
differ
acut
recoveri
phase
analyz
pair
ttest
normal
distribut
wilcoxon
rank
sum
test
nonparametr
distribut
correl
coeffici
select
variabl
calcul
spearman
rank
correl
analysi
receiv
oper
characterist
roc
curv
construct
evalu
perform
characterist
specif
csf
chemokin
differenti
hfmd
patient
enceph
fc
patient
twotail
p
valu
consid
statist
signific
dataset
gener
andor
analyz
current
studi
avail
correspond
author
reason
request
